The pathogen Clostridioides difficile (C. difficile) is naturally present in the intestines of many people. When present in ...

New clinical data show omilancor reduced a molecular signature associated with biologic refractoriness by more than 55% in ulcerative colitis and Crohn’s disease patients. Omila ...

A new review in Gut Pathogens argues that SARS-CoV-2 infection and COVID-19 care pathways may create gut conditions ...

Monthly long-form interviews will air on Bloomberg Television across four regions and on New to The Street TV's YouTube ...

Ajay Goel, PhD, AGAF, explains the significance of 2 new studies that found that early-onset colorectal cancer (EOCRC) and recurrence in CRC could both be predicted using new blood and tissue tests.

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported ...

Three widely used drug classes have quietly lost ground in the evidence, yet many Americans over 65 are still on them today.

Colleen Kelly, MD, discusses emerging applications for FMT, the challenges of treating obesity in IBD, and why human ...

Acurx Pharmaceuticals (ISIN US00510M2035) remains tied to a USD 10.00 analyst target after Stock Analysis reported on ...

Immuron reported FY26 global sales revenue of A$7.7 million, up 6% year-on-year, supported by growth across Australia and the United States. The company expanded its commercial portfolio through ...

Detailed price information for Redhill Biophrma ADR (RDHL-Q) from The Globe and Mail including charting and trades.